According to Zacks, “Exactech, Inc. develops, manufactures, markets and distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. Its principal products include its knee and hip replacement systems. Exactech, Inc. is headquartered in Gainesville, Florida. “
Exactech (NASDAQ:EXAC) opened at 26.54 on Tuesday. The stock has a market cap of $375.51 million, a price-to-earnings ratio of 23.91 and a beta of 0.86. The firm’s 50-day moving average is $27.43 and its 200 day moving average is $25.28. Exactech has a 52 week low of $16.11 and a 52 week high of $28.66.
Exactech (NASDAQ:EXAC) last issued its earnings results on Monday, August 1st. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.30 by $0.01. The company had revenue of $66.10 million for the quarter, compared to analyst estimates of $64.18 million. Exactech had a net margin of 6.32% and a return on equity of 6.84%. The business’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 EPS. On average, equities research analysts expect that Exactech will post $1.18 EPS for the current year.
In other news, CEO David W. Petty sold 3,550 shares of Exactech stock in a transaction on Friday, August 19th. The stock was sold at an average price of $27.75, for a total transaction of $98,512.50. Following the completion of the transaction, the chief executive officer now owns 63,122 shares of the company’s stock, valued at approximately $1,751,635.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Bruce E. Thompson sold 1,433 shares of Exactech stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $27.97, for a total value of $40,081.01. Following the transaction, the senior vice president now directly owns 25,375 shares of the company’s stock, valued at approximately $709,738.75. The disclosure for this sale can be found here. Company insiders own 29.80% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in EXAC. Public Employees Retirement System of Ohio increased its position in Exactech by 36.3% in the second quarter. Public Employees Retirement System of Ohio now owns 3,740 shares of the company’s stock valued at $100,000 after buying an additional 997 shares during the period. BlackRock Inc. increased its position in Exactech by 1,291.6% in the second quarter. BlackRock Inc. now owns 5,274 shares of the company’s stock valued at $141,000 after buying an additional 4,895 shares during the period. Acrospire Investment Management LLC purchased a new position in Exactech during the first quarter valued at about $143,000. American International Group Inc. increased its position in Exactech by 0.6% in the second quarter. American International Group Inc. now owns 6,007 shares of the company’s stock valued at $161,000 after buying an additional 38 shares during the period. Finally, Metropolitan Life Insurance Co. NY purchased a new position in Exactech during the first quarter valued at about $173,000. 65.08% of the stock is owned by institutional investors and hedge funds.
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee implants, hip implants, biologics and spine, extremity implants and other products. Its other products segment includes surgical instruments, bone cement and other implant product lines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.